GlassScriptPhysician profile
William J Harb
NPI 1063528651
$7,654.99
in general payments reported to CMS, 2019-2025
31 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $364 · 2021: $3,878 · 2022: $658 · 2023: $546 · 2024: $590 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414 · Consulting Fee: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.27 |
| Consulting Fee | $212.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $3,950.00 | 2021-2023 | Precisetumor |
| Medtronic USA, INC. | $970.87 | 2019-2020 | |
| Braintree Laboratories, INC. | $647.12 | 2019-2025 | Suflave, Sutab |
| Medtronic, INC. | $512.63 | 2021-2023 | Interstim, Ligasure |
| Integra Lifesciences Corporation | $239.77 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Conmed Corporation | $174.51 | 2024 | Airseal |
| Olympus America INC. | $127.24 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $117.00 | 2024 | Gore Synecor Biomaterial |
| Acell, INC. | $107.99 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $89.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.12 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $79.87 | 2020-2025 | Entyvio |
| Thd America, INC. | $70.26 | 2019-2023 | |
| Laborie Medical Technologies Corp. | $51.38 | 2022-2024 | |
| Axonics, INC. | $42.42 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $40.56 | 2022-2023 | Seglentis |
| Janssen Biotech, INC. | $40.18 | 2023-2024 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $39.90 | 2024-2025 | Voquezna |
| Gi Supply, INC. | $36.46 | 2022 | |
| Aroa Biosurgery Incorporated | $26.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.78 | 2023 | Dupixent |
| Innovation Technologies INC | $23.89 | 2025 | Irrisept |
| Micro-Tech Endoscopy USA, INC. | $23.53 | 2020-2025 | |
| Acera Surgical, INC. | $18.52 | 2023 | Restrata Wound Matrix |
| Merck Sharp & Dohme LLC | $17.68 | 2019 | |
| Boston Scientific Corporation | $17.45 | 2025 | Bulkamid |
| Gilead Sciences, INC. | $17.04 | 2020 | |
| Qol Medical, LLC | $16.51 | 2025 | Sucraid |
| Abbvie INC. | $16.35 | 2025 | |
| Trevena, INC. | $14.49 | 2021 | |
| Shire North American Group INC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.